All In Biotech

Drug Trial Radar · NCT07584226

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 9, 2026

Primary completion

May 31, 2029

Study completion Jun 30, 2031

Sponsor

Lead sponsor
Relay Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma, colorectal and other solid tumors.

Conditions

  • Advanced NRAS-Mutant Melanoma
  • Advanced NRAS-Mutant Solid Tumors
  • NRAS Mutation
  • NRAS G12D
  • NRAS G13R
  • NRAS G13D
  • NRAS G12V
  • NRAS Q61R
  • NRAS Q61K
  • NRAS Q61L
  • NRAS Q61H
  • Advanced NRAS-mutant Colorectal Cancer

Interventions

  • RLY-8161Drug

    RLY-8161 is an NRAS-selective inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum Tolerated Dose (MTD) and/or RP2D of RLY-8161Time frame: Cycle 1 (28-day cycle) of treatment for MTD and at the end of every cycle (28-day cycle) for RP2D until treatment discontinuation, approximately 12 months
  2. Part 1: Number of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs), with changes in vital signs, electrocardiograms (ECGs), and laboratory testsTime frame: Cycle 1 (28-day cycle) of treatment and at the end of every cycle (28-day cycle) until 30 days after treatment discontinuation, approximately 13 months
  3. Part 2: Objective Response Rate (ORR) of RLY-8161 as assessed by RECIST v1.1Time frame: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • START Midwest, LLC

    Grand Rapids, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Sarah Cannon Research Institute Oncology Partners

    Nashville, Tennessee · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.